Lantern Pharma Inc. LTRN
Lantern Pharma Inc. (Nasdaq: LTRN) is an oncology drug developer. Its lead program, LP-300 (Harmonic trial), is in Phase 2 for never-smoker non-small cell lung cancer (NSCLC), in combination with chemotherapy; focus on EGFR exon 21 L858R.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| LP-300 (Harmonic) | never-smoker NSCLC | small molecule | Phase 2 |
| LP-184 (STAR-001 in CNS) | solid tumors incl. TNBC, NSCLC (KEAP1/STK11), GBM | small molecule | Phase 1 |
| LP-284 | hematological cancers | small molecule | Phase 1 |
| LP-100 | prostate cancer in combination with PARP inhibitors | small molecule | Pre-clinical |
| ADC program (cryptophycin payload) | solid tumors | biologic-other | Pre-clinical |
Recent results and decisions
- Aug 14, 2026positive Emerging Phase 2 data (May 11, 2026 cutoff): median PFS 8.9 months in L858R patients completing six cycles (n=9) vs 8.4 months in overall L858R cohort (n=16); HR 0.37 in L858R subgroup; small exploratory cohorts.
Median progression-free survival reached 8.9 months among L858R patients who completed six cycles of LP-300 (n=9, of whom three had not progressed at the time of analysis), compared with 8.4 months across the overall L858R cohort (n=16).
Filing - Aug 14, 2026n/a European Medicines Agency cleared an investigator-initiated Phase 1b/2 trial of LP-184 in biomarker-selected advanced bladder cancer.
In July 2026, the European Medicines Agency cleared an investigator-initiated Phase 1b/2 clinical trial of LP-184 (zirdafulven) in advanced, recurrent bladder cancer.
Filing - Mar 30, 2026n/a FDA cleared the IND for Starlight Therapeutics' planned Phase 1 pediatric CNS cancer trial of STAR-001 (LP-184).
In early 2026, the FDA cleared the IND for Starlight Therapeutics’ planned Phase 1 pediatric CNS cancer trial of STAR-001 (LP-184) in Atypical Teratoid Rhabdoid Tumor (ATRT) and other rare pediatric cancers.
Filing
1 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Puma Biotechnology, Inc. PBYI
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.